New York State Common Retirement Fund Sells 183,141 Shares of Perrigo Company plc (NYSE:PRGO)

New York State Common Retirement Fund decreased its position in Perrigo Company plc (NYSE:PRGO - Free Report) by 49.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 187,679 shares of the company's stock after selling 183,141 shares during the quarter. New York State Common Retirement Fund owned 0.14% of Perrigo worth $6,040,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Qube Research & Technologies Ltd acquired a new position in Perrigo in the third quarter worth $5,447,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Perrigo during the 3rd quarter worth about $2,006,000. Teachers Retirement System of The State of Kentucky increased its position in Perrigo by 94.1% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 46,118 shares of the company's stock valued at $1,473,000 after acquiring an additional 22,354 shares in the last quarter. abrdn plc bought a new position in shares of Perrigo in the fourth quarter worth about $1,422,000. Finally, Patriot Financial Group Insurance Agency LLC increased its holdings in shares of Perrigo by 4.1% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 9,627 shares of the company's stock valued at $310,000 after purchasing an additional 380 shares in the last quarter. Institutional investors and hedge funds own 95.91% of the company's stock.

Perrigo Trading Down 0.8 %

NYSE:PRGO traded down $0.27 during mid-day trading on Friday, hitting $32.79. The company had a trading volume of 981,835 shares, compared to its average volume of 1,163,526. The firm has a market cap of $4.44 billion, a P/E ratio of -327.80 and a beta of 0.63. Perrigo Company plc has a fifty-two week low of $25.77 and a fifty-two week high of $40.28. The business's fifty day moving average is $30.60 and its two-hundred day moving average is $30.89. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.07 and a current ratio of 1.79.

Perrigo (NYSE:PRGO - Get Free Report) last released its quarterly earnings data on Tuesday, February 27th. The company reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.17 billion. Perrigo had a negative net margin of 0.27% and a positive return on equity of 7.34%. Perrigo's quarterly revenue was up .1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.75 EPS. As a group, research analysts expect that Perrigo Company plc will post 2.55 earnings per share for the current year.

Perrigo Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 18th. Shareholders of record on Friday, May 31st will be issued a dividend of $0.276 per share. The ex-dividend date is Friday, May 31st. This represents a $1.10 annualized dividend and a yield of 3.37%. Perrigo's dividend payout ratio is presently -1,100.00%.

Insider Buying and Selling at Perrigo

In other Perrigo news, EVP Alison Ives acquired 2,490 shares of the business's stock in a transaction dated Tuesday, March 5th. The shares were acquired at an average price of $27.26 per share, for a total transaction of $67,877.40. Following the acquisition, the executive vice president now directly owns 16,122 shares of the company's stock, valued at approximately $439,485.72. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Perrigo news, EVP Robert Willis acquired 6,000 shares of the stock in a transaction dated Thursday, February 29th. The shares were bought at an average cost of $25.87 per share, for a total transaction of $155,220.00. Following the completion of the acquisition, the executive vice president now directly owns 25,105 shares of the company's stock, valued at $649,466.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Alison Ives bought 2,490 shares of Perrigo stock in a transaction that occurred on Tuesday, March 5th. The shares were acquired at an average price of $27.26 per share, with a total value of $67,877.40. Following the acquisition, the executive vice president now directly owns 16,122 shares of the company's stock, valued at approximately $439,485.72. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 17,990 shares of company stock valued at $475,227. Company insiders own 0.70% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on PRGO shares. Piper Sandler increased their price objective on Perrigo from $35.00 to $39.00 and gave the company an "overweight" rating in a research report on Monday, April 8th. StockNews.com raised Perrigo from a "hold" rating to a "buy" rating in a report on Wednesday, April 3rd. JPMorgan Chase & Co. reduced their target price on shares of Perrigo from $48.00 to $41.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 28th. Finally, Canaccord Genuity Group restated a "buy" rating and issued a $42.00 price objective on shares of Perrigo in a report on Friday, April 12th.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.